pharmacological studies

OTHER2 trials

Sponsors

City of Hope Medical Center, Vanderbilt-Ingram Cancer Center

Conditions

Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachEstrogen Receptor-positive Breast CancerHER2-negative Breast CancerIntestinal Adenocarcinoma of the StomachInvasive Ductal Breast CarcinomaMixed Adenocarcinoma of the Stomach

Phase 1

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Active, not recruitingNCT01791478

Vanderbilt-Ingram Cancer CenterEstrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma +3

Start: 2013-04-30End: 2025-02-28Updated: 2024-07-23

Phase 2

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

CompletedNCT01612546

City of Hope Medical CenterAdenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach +11

Start: 2012-11-30End: 2015-01-15Updated: 2018-02-01

Related Papers

Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC).

Journal of Clinical Oncology2016-02-011 citations

Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing

Molecular Cancer Therapeutics2015-12-01

Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer

Cancer Research2015-08-013 citations

SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).

Journal of Clinical Oncology2014-05-203 citations